KR20170027868A - 조직 보호 펩티드 및 이의 용도 - Google Patents
조직 보호 펩티드 및 이의 용도 Download PDFInfo
- Publication number
- KR20170027868A KR20170027868A KR1020177005579A KR20177005579A KR20170027868A KR 20170027868 A KR20170027868 A KR 20170027868A KR 1020177005579 A KR1020177005579 A KR 1020177005579A KR 20177005579 A KR20177005579 A KR 20177005579A KR 20170027868 A KR20170027868 A KR 20170027868A
- Authority
- KR
- South Korea
- Prior art keywords
- peptide
- tissue protective
- amino acid
- seq
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70574105P | 2005-08-05 | 2005-08-05 | |
| US60/705,741 | 2005-08-05 | ||
| US70627605P | 2005-08-08 | 2005-08-08 | |
| US60/706,276 | 2005-08-08 | ||
| US83173706P | 2006-07-18 | 2006-07-18 | |
| US60/831,737 | 2006-07-18 | ||
| PCT/US2006/031061 WO2007019545A2 (en) | 2005-08-05 | 2006-08-07 | Tissue protective peptides and uses thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137016015A Division KR101713368B1 (ko) | 2005-08-05 | 2006-08-07 | 조직 보호 펩티드 및 이의 용도 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187016750A Division KR20180067735A (ko) | 2005-08-05 | 2006-08-07 | 조직 보호 펩티드 및 이의 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20170027868A true KR20170027868A (ko) | 2017-03-10 |
Family
ID=37728020
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177005579A Ceased KR20170027868A (ko) | 2005-08-05 | 2006-08-07 | 조직 보호 펩티드 및 이의 용도 |
| KR1020137016015A Expired - Fee Related KR101713368B1 (ko) | 2005-08-05 | 2006-08-07 | 조직 보호 펩티드 및 이의 용도 |
| KR1020187030050A Ceased KR20180116475A (ko) | 2005-08-05 | 2006-08-07 | 조직 보호 펩티드 및 이의 용도 |
| KR1020187016750A Ceased KR20180067735A (ko) | 2005-08-05 | 2006-08-07 | 조직 보호 펩티드 및 이의 용도 |
| KR1020197019568A Ceased KR20190084136A (ko) | 2005-08-05 | 2006-08-07 | 조직 보호 펩티드 및 이의 용도 |
| KR1020087005373A Expired - Fee Related KR101626153B1 (ko) | 2005-08-05 | 2006-08-07 | 조직 보호 펩티드 및 이의 용도 |
| KR1020207016998A Ceased KR20200072568A (ko) | 2005-08-05 | 2006-08-07 | 조직 보호 펩티드 및 이의 용도 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137016015A Expired - Fee Related KR101713368B1 (ko) | 2005-08-05 | 2006-08-07 | 조직 보호 펩티드 및 이의 용도 |
| KR1020187030050A Ceased KR20180116475A (ko) | 2005-08-05 | 2006-08-07 | 조직 보호 펩티드 및 이의 용도 |
| KR1020187016750A Ceased KR20180067735A (ko) | 2005-08-05 | 2006-08-07 | 조직 보호 펩티드 및 이의 용도 |
| KR1020197019568A Ceased KR20190084136A (ko) | 2005-08-05 | 2006-08-07 | 조직 보호 펩티드 및 이의 용도 |
| KR1020087005373A Expired - Fee Related KR101626153B1 (ko) | 2005-08-05 | 2006-08-07 | 조직 보호 펩티드 및 이의 용도 |
| KR1020207016998A Ceased KR20200072568A (ko) | 2005-08-05 | 2006-08-07 | 조직 보호 펩티드 및 이의 용도 |
Country Status (25)
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030072737A1 (en) * | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| US9345745B2 (en) * | 2005-04-29 | 2016-05-24 | Bo Wang | Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides |
| WO2007052154A2 (en) | 2005-04-29 | 2007-05-10 | University Of Medicine And Dentistry Of New Jersey | Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators |
| US9585932B2 (en) * | 2005-04-29 | 2017-03-07 | Peter C. Dowling | Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders |
| EP1924276A4 (en) * | 2005-08-05 | 2009-07-22 | Araim Pharmaceuticals Inc | Antiperspirant peptides and their uses |
| CN101460188B (zh) * | 2006-06-07 | 2013-09-04 | 国立大学法人德岛大学 | 使用促红细胞生成素的局部缺血疾病的治疗 |
| DK2081956T3 (da) * | 2006-11-13 | 2013-06-24 | Charite Universitaetsmedizin | FREMGANGSMÅDE TIL CELLEDYRKNING OG FREMGANGSMÅDE TIL BEHANDLING OMFATTENDE EN vEPO-PROTEINVARIANT |
| WO2009094172A2 (en) * | 2008-01-22 | 2009-07-30 | Araim Pharmaceuticals, Inc. | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
| AU2016203452B2 (en) * | 2008-01-22 | 2018-02-22 | Araim Pharmaceuticals, Inc. | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
| AU2014203195B2 (en) * | 2008-01-22 | 2016-03-31 | Araim Pharmaceuticals, Inc. | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
| WO2012051581A2 (en) * | 2010-10-14 | 2012-04-19 | Rutgers, The State University Of New Jersey | Intestinal peptide targeting ligands |
| US9566349B2 (en) * | 2010-10-14 | 2017-02-14 | Rutgers, The State University Of New Jersey | Intestinal peptide targeting ligands |
| CN102180948A (zh) * | 2011-03-03 | 2011-09-14 | 复旦大学附属中山医院 | 一种具有肾脏保护作用的短肽及其制备方法和应用 |
| CN102212111B (zh) * | 2011-05-05 | 2014-04-30 | 中国人民解放军第三军医大学 | 小分子多肽和小分子多肽脂质体及其运用 |
| EP2736530B1 (en) * | 2011-07-27 | 2018-06-06 | Neumedicines, Inc | Use of il-12 to generate endogenous erythropoietin |
| US20140249573A1 (en) * | 2011-09-20 | 2014-09-04 | A.A. Cash Technology Ltd. | Methods and devices for occluding blood flow to an organ |
| KR101148191B1 (ko) * | 2011-09-27 | 2012-05-23 | 김후정 | 에리스로포이에틴-유래 펩타이드 및 그 용도 |
| WO2013158871A1 (en) * | 2012-04-20 | 2013-10-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of erythropoietin and derivatives for treating hypertension |
| CN105517561A (zh) * | 2013-07-17 | 2016-04-20 | 阿拉伊姆药品公司 | 预防和治疗组织损伤相关疾病和病症的组织保护肽和肽类似物 |
| CN104744593A (zh) * | 2013-12-25 | 2015-07-01 | 深圳先进技术研究院 | 一种抗肿瘤血管生成免疫复合肽及其制备方法和应用 |
| US9622483B2 (en) | 2014-02-19 | 2017-04-18 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| US11039621B2 (en) | 2014-02-19 | 2021-06-22 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| US11039620B2 (en) | 2014-02-19 | 2021-06-22 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| KR20150130616A (ko) * | 2014-05-13 | 2015-11-24 | (주)케어젠 | 피부상태 개선 활성을 갖는 펩타이드 및 이의 용도 |
| CN105968172A (zh) * | 2014-06-22 | 2016-09-28 | 马恒标 | 组织保护活性多肽sl2及其应用 |
| WO2017066454A2 (en) | 2015-10-14 | 2017-04-20 | X-Therma, Inc. | Compositions and methods for reducing ice crystal formation |
| JP2019523633A (ja) | 2016-04-29 | 2019-08-29 | アライム ファーマシューティカルズ,インコーポレーテッド | 組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド |
| ES2952448T3 (es) | 2016-11-10 | 2023-10-31 | Asc Regenity Ltd | Formulaciones cosméticas para aplicaciones tópicas que contienen moléculas derivadas de eritropoyetina |
| CN110475786A (zh) * | 2017-02-27 | 2019-11-19 | 大邱庆北科学技术院 | 红细胞生成素衍生肽通过其对预防细胞损伤的作用的用途 |
| WO2018157773A1 (zh) | 2017-02-28 | 2018-09-07 | 暨南大学 | 一种促进创伤后组织修复与再生的修复肽及其应用 |
| CN108503690B (zh) * | 2017-02-28 | 2020-07-03 | 暨南大学 | 一种促进创伤后组织修复与再生的修复肽及其应用 |
| US20210244791A1 (en) * | 2018-04-08 | 2021-08-12 | Brim Biotechnology, Inc. | Application of pedf-derived short peptides in tendon healing |
| KR102300060B1 (ko) | 2018-06-12 | 2021-09-08 | 주식회사 엘지에너지솔루션 | 2열 터미널 구조의 pcb 다이렉트 커넥터 |
| WO2020055768A1 (en) | 2018-09-10 | 2020-03-19 | Cold Spring Harbor Laboratory | Methods for treating pancreatitis |
| CN112390877B (zh) * | 2019-08-16 | 2022-10-04 | 董红燕 | Pedf衍生多肽组合物及其在制备保护肺损伤药物中的应用 |
| CN118255845B (zh) * | 2022-12-27 | 2025-07-11 | 上海瑞吉康生物医药有限公司 | 相分离逆转多肽的变体及其应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO812612L (no) | 1980-08-06 | 1982-02-08 | Ferring Pharma Ltd | Enzym-inhibitorer. |
| US4558006A (en) | 1983-02-04 | 1985-12-10 | Kirin-Amgen, Inc. | A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin |
| US5051448A (en) | 1984-07-24 | 1991-09-24 | The Mclean Hospital Corporation | GABA esters and GABA analog esters |
| US4704355A (en) | 1985-03-27 | 1987-11-03 | New Horizons Diagnostics Corporation | Assay utilizing ATP encapsulated within liposome particles |
| US4798824A (en) | 1985-10-03 | 1989-01-17 | Wisconsin Alumni Research Foundation | Perfusate for the preservation of organs |
| US5498694A (en) | 1989-05-25 | 1996-03-12 | La Jolla Cancer Research Foundation | Peptides of the cytoplasmic domain of integrin |
| DE3924746A1 (de) * | 1989-07-26 | 1991-01-31 | Behringwerke Ag | Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper |
| CA2025907A1 (en) | 1989-09-21 | 1991-03-22 | Franklin D. Collins | Method of transporting compositions across the blood brain barrier |
| US5192746A (en) | 1990-07-09 | 1993-03-09 | Tanabe Seiyaku Co., Ltd. | Cyclic cell adhesion modulation compounds |
| US6140120A (en) * | 1993-02-12 | 2000-10-31 | Board Of Trustees Of Leland Stanford Jr. University | Regulated transcription of targeted genes and other biological events |
| US5559103A (en) | 1993-07-21 | 1996-09-24 | Cytel Corporation | Bivalent sialyl X saccharides |
| US5571787A (en) | 1993-07-30 | 1996-11-05 | Myelos Corporation | Prosaposin as a neurotrophic factor |
| US5700909A (en) | 1993-07-30 | 1997-12-23 | The Regents Of The University Of California | Prosaposin and cytokine-derived peptides |
| WO1995021919A2 (en) * | 1994-02-14 | 1995-08-17 | Kirin Brewery Company, Limited | Protein having tpo activity |
| ITFI940106A1 (it) * | 1994-05-27 | 1995-11-27 | Menarini Ricerche Sud Spa | Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica |
| US5576423A (en) | 1994-12-02 | 1996-11-19 | Schering Corporation | Antibodies to the slam protein expressed on activated T cells |
| BR9609006A (pt) * | 1995-06-07 | 1999-12-14 | Ortho Pharma Corp | Peptìdeo, composição farmacêutica, e, processo para tratamento dse paciente. |
| AU4267297A (en) * | 1997-09-11 | 1998-09-22 | Regents Of The University Of California, The | Method of alleviating neuropathic pain |
| US7270809B2 (en) * | 1997-07-14 | 2007-09-18 | Bolder Biotechnology, Inc. | Cysteine variants of alpha interferon-2 |
| US7153943B2 (en) * | 1997-07-14 | 2006-12-26 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins, and methods of use thereof |
| TR200103785T2 (tr) | 1999-04-13 | 2002-06-21 | The Kenneth S. Warren Institute, Inc. | Uyarılabilir doku işlevinin periferik olarak uygulanan eritropoietin vasıtasıyla düzenlenmesi |
| WO2001083548A1 (en) * | 2000-04-28 | 2001-11-08 | Effector Cell Institute | Novel derivative of cell chemotactic factor |
| AU3323002A (en) * | 2000-12-20 | 2002-07-01 | Hoffmann La Roche | Erythropoietin conjugates |
| US20030072737A1 (en) | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| PA8536201A1 (es) | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina |
| JP2004522445A (ja) * | 2001-02-06 | 2004-07-29 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 低減された免疫原性を有する修飾されたエリスロポエチン(epo) |
| JP2005503127A (ja) * | 2001-04-04 | 2005-02-03 | ジェンオディセ | エリスロポエチン遺伝子の新規ポリヌクレオチド及びポリペプチド |
| KR100467751B1 (ko) * | 2001-12-03 | 2005-01-24 | 씨제이 주식회사 | 생체내 에리스로포이에틴 활성이 증진된 융합단백질 |
| US7300915B2 (en) * | 2002-06-05 | 2007-11-27 | The Regents Of The University Of California | Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain |
| MXPA05000063A (es) | 2002-07-01 | 2005-04-08 | Kenneth S Warren Inst Inc | Citocinas recombinantes protectoras de tejido y acidos nucleicos que las codifican para la proteccion, restauracion y mejora de celulas, tejidos y organos respondedores. |
| KR100478455B1 (ko) | 2002-08-19 | 2005-03-22 | 삼성전자주식회사 | 전자렌지 |
| WO2005025606A1 (en) | 2003-09-09 | 2005-03-24 | Warren Pharmaceuticals, Inc. | Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin |
| ZA200505423B (en) | 2002-09-09 | 2008-08-27 | Warren Pharmaceuticals Inc | Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin |
| JP2006512300A (ja) * | 2002-10-03 | 2006-04-13 | エピミューン インコーポレイテッド | Hla結合ペプチド及びその使用 |
| JP2004305006A (ja) * | 2003-04-01 | 2004-11-04 | Japan Science & Technology Agency | 人工調製肺サーファクタント |
| ATE482713T1 (de) * | 2003-04-25 | 2010-10-15 | Univ Pittsburgh | Von muskeln stammende zellen (mdcs) zur förderung und verbesserung der nervenreparatur und - regeneration |
| US7718363B2 (en) | 2003-04-25 | 2010-05-18 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
| CN1897959A (zh) | 2003-09-29 | 2007-01-17 | 沃伦药品公司 | 用于治疗和预防脓毒病和粘连形成的组织保护细胞因子 |
| US20080227696A1 (en) * | 2005-02-22 | 2008-09-18 | Biosurface Engineering Technologies, Inc. | Single branch heparin-binding growth factor analogs |
| WO2007010552A2 (en) | 2005-03-17 | 2007-01-25 | Serum Institute Of India Limited | N- terminal peg conjugate of erythropoietin |
| US9345745B2 (en) | 2005-04-29 | 2016-05-24 | Bo Wang | Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides |
| WO2007052154A2 (en) | 2005-04-29 | 2007-05-10 | University Of Medicine And Dentistry Of New Jersey | Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators |
| EP2377884A1 (en) | 2005-05-10 | 2011-10-19 | Neoloch Aps | Neuritogenic peptides |
| EP1736481A1 (en) | 2005-05-13 | 2006-12-27 | Charite Universitätsmedizin-Berlin | Erythropoietin variants |
| WO2006127910A2 (en) | 2005-05-25 | 2006-11-30 | Neose Technologies, Inc. | Glycopegylated erythropoietin formulations |
| EP1924276A4 (en) | 2005-08-05 | 2009-07-22 | Araim Pharmaceuticals Inc | Antiperspirant peptides and their uses |
| ATE554186T1 (de) | 2007-11-29 | 2012-05-15 | Molecular Health Gmbh | Eph-b4 spezifische sirna zur reduktion von epo- induziertem tumorzellwachstum während anämiebehandlung in krebspatienten, gewebeschutz- erythropoietin-rezeptor (nepor) und verfahren zu seiner verwendung |
| WO2009094172A2 (en) | 2008-01-22 | 2009-07-30 | Araim Pharmaceuticals, Inc. | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
| EP2297182A4 (en) * | 2008-04-28 | 2012-08-15 | Harvard College | HIGHLY CHARGED PROTEINS USED FOR CELL PENETRATION |
| WO2011022056A2 (en) | 2009-08-18 | 2011-02-24 | Medical College Of Georgia Research Institute, Inc. | PEPTIDE MODULATORS OF THE δPKC INTERACTION WITH THE D SUBUNIT OF F1FO ATP SYNTHASE/ATPASE AND USES THEREOF |
-
2006
- 2006-08-07 EP EP06801051A patent/EP1924276A4/en not_active Withdrawn
- 2006-08-07 HU HUE11163194A patent/HUE026444T2/en unknown
- 2006-08-07 BR BRPI0614529A patent/BRPI0614529A8/pt not_active Application Discontinuation
- 2006-08-07 KR KR1020177005579A patent/KR20170027868A/ko not_active Ceased
- 2006-08-07 KR KR1020137016015A patent/KR101713368B1/ko not_active Expired - Fee Related
- 2006-08-07 DK DK12175352.9T patent/DK2540309T3/en active
- 2006-08-07 US US11/997,898 patent/US8071554B2/en not_active Expired - Fee Related
- 2006-08-07 SI SI200631979T patent/SI2371855T1/sl unknown
- 2006-08-07 HU HUE12175366A patent/HUE035655T2/en unknown
- 2006-08-07 MX MX2014011168A patent/MX339613B/es unknown
- 2006-08-07 AU AU2006278264A patent/AU2006278264B2/en not_active Ceased
- 2006-08-07 PT PT121753669T patent/PT2594279T/pt unknown
- 2006-08-07 LT LTEP12175366.9T patent/LT2594279T/lt unknown
- 2006-08-07 PL PL11163194T patent/PL2371855T3/pl unknown
- 2006-08-07 ES ES12175352.9T patent/ES2653864T3/es not_active Expired - Lifetime
- 2006-08-07 KR KR1020187030050A patent/KR20180116475A/ko not_active Ceased
- 2006-08-07 IN IN2050CHN2014 patent/IN2014CN02050A/en unknown
- 2006-08-07 SG SG2014007868A patent/SG2014007868A/en unknown
- 2006-08-07 KR KR1020187016750A patent/KR20180067735A/ko not_active Ceased
- 2006-08-07 SI SI200632233T patent/SI2540309T1/en unknown
- 2006-08-07 MX MX2016004825A patent/MX364100B/es unknown
- 2006-08-07 PT PT121753529T patent/PT2540309T/pt unknown
- 2006-08-07 UA UAA200802850A patent/UA100222C2/uk unknown
- 2006-08-07 PL PL12175352T patent/PL2540309T3/pl unknown
- 2006-08-07 CA CA2982909A patent/CA2982909A1/en not_active Abandoned
- 2006-08-07 DK DK11163194.1T patent/DK2371855T3/en active
- 2006-08-07 LT LTEP12175352.9T patent/LT2540309T/lt unknown
- 2006-08-07 KR KR1020197019568A patent/KR20190084136A/ko not_active Ceased
- 2006-08-07 NZ NZ565937A patent/NZ565937A/en not_active IP Right Cessation
- 2006-08-07 KR KR1020087005373A patent/KR101626153B1/ko not_active Expired - Fee Related
- 2006-08-07 JP JP2008525285A patent/JP5274253B2/ja not_active Expired - Fee Related
- 2006-08-07 CN CN2006800348244A patent/CN101378772B/zh not_active Expired - Fee Related
- 2006-08-07 CN CN201310529242.5A patent/CN103724418B/zh not_active Expired - Fee Related
- 2006-08-07 EP EP12175352.9A patent/EP2540309B1/en not_active Expired - Lifetime
- 2006-08-07 DK DK12175366.9T patent/DK2594279T3/en active
- 2006-08-07 EP EP11163194.1A patent/EP2371855B1/en not_active Expired - Lifetime
- 2006-08-07 MX MX2008001509A patent/MX2008001509A/es active IP Right Grant
- 2006-08-07 SI SI200632230T patent/SI2594279T1/en unknown
- 2006-08-07 CA CA2618396A patent/CA2618396C/en not_active Expired - Fee Related
- 2006-08-07 KR KR1020207016998A patent/KR20200072568A/ko not_active Ceased
- 2006-08-07 ES ES12175366.9T patent/ES2653790T3/es not_active Expired - Lifetime
- 2006-08-07 EA EA200800536A patent/EA015672B1/ru not_active IP Right Cessation
- 2006-08-07 EP EP17202352.5A patent/EP3363451A1/en not_active Withdrawn
- 2006-08-07 ES ES11163194.1T patent/ES2550055T3/es not_active Expired - Lifetime
- 2006-08-07 EP EP12175366.9A patent/EP2594279B1/en not_active Expired - Lifetime
- 2006-08-07 HU HUE12175352A patent/HUE035793T2/en unknown
- 2006-08-07 PT PT111631941T patent/PT2371855E/pt unknown
- 2006-08-07 SG SG10201805825SA patent/SG10201805825SA/en unknown
- 2006-08-07 CA CA3079319A patent/CA3079319A1/en not_active Abandoned
- 2006-08-07 WO PCT/US2006/031061 patent/WO2007019545A2/en not_active Ceased
- 2006-08-07 PL PL12175366T patent/PL2594279T3/pl unknown
-
2008
- 2008-02-05 IL IL189287A patent/IL189287A/en active IP Right Grant
- 2008-03-03 NO NO20081112A patent/NO20081112L/no not_active Application Discontinuation
-
2011
- 2011-03-11 ZA ZA2011/01890A patent/ZA201101890B/en unknown
- 2011-10-20 US US13/278,131 patent/US8716245B2/en not_active Expired - Fee Related
-
2012
- 2012-04-16 US US13/448,345 patent/US8673861B2/en not_active Expired - Fee Related
-
2013
- 2013-02-15 JP JP2013027479A patent/JP5918155B2/ja not_active Expired - Fee Related
-
2014
- 2014-04-08 US US14/248,030 patent/US9340598B2/en not_active Expired - Fee Related
-
2015
- 2015-02-04 JP JP2015020020A patent/JP6158235B2/ja not_active Expired - Fee Related
- 2015-02-10 US US14/618,873 patent/US20150152156A1/en not_active Abandoned
- 2015-06-29 IL IL239695A patent/IL239695A0/en active IP Right Grant
-
2016
- 2016-05-05 US US15/147,848 patent/US10100096B2/en not_active Expired - Fee Related
- 2016-06-08 JP JP2016114010A patent/JP6491621B2/ja not_active Expired - Fee Related
-
2018
- 2018-04-03 JP JP2018071318A patent/JP2018134084A/ja active Pending
- 2018-08-23 IL IL261346A patent/IL261346A/en unknown
- 2018-09-25 US US16/141,724 patent/US20190016769A1/en not_active Abandoned
-
2020
- 2020-01-30 JP JP2020013151A patent/JP2020078317A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101713368B1 (ko) | 조직 보호 펩티드 및 이의 용도 | |
| AU2013201291B2 (en) | Tissue protective peptides and uses thereof | |
| AU2020201658A1 (en) | Tissue protective peptides and uses thereof | |
| HK1261413A1 (en) | Tissue protective peptides and uses thereof | |
| HK1196622A (en) | Tissue protective peptides and uses thereof | |
| HK1127751B (en) | Tissue protective peptides and uses thereof | |
| HK1185546B (en) | Tissue protective peptides and uses thereof | |
| HK1196622B (en) | Tissue protective peptides and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20170227 Application number text: 1020137016015 Filing date: 20130620 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| AMND | Amendment | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20170329 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20170609 Patent event code: PE09021S01D |
|
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20180213 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20170609 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| J201 | Request for trial against refusal decision | ||
| PJ0201 | Trial against decision of rejection |
Patent event date: 20180514 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20180213 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Decision date: 20190627 Appeal identifier: 2018101002079 Request date: 20180514 |
|
| A107 | Divisional application of patent | ||
| AMND | Amendment | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20180612 Application number text: 1020137016015 Filing date: 20130620 |
|
| PB0901 | Examination by re-examination before a trial |
Comment text: Amendment to Specification, etc. Patent event date: 20180612 Patent event code: PB09011R02I Comment text: Request for Trial against Decision on Refusal Patent event date: 20180514 Patent event code: PB09011R01I Comment text: Amendment to Specification, etc. Patent event date: 20171010 Patent event code: PB09011R02I Comment text: Amendment to Specification, etc. Patent event date: 20170329 Patent event code: PB09011R02I |
|
| B601 | Maintenance of original decision after re-examination before a trial | ||
| PB0601 | Maintenance of original decision after re-examination before a trial | ||
| J301 | Trial decision |
Free format text: TRIAL NUMBER: 2018101002079; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20180514 Effective date: 20190627 |
|
| PJ1301 | Trial decision |
Patent event code: PJ13011S01D Patent event date: 20190627 Comment text: Trial Decision on Objection to Decision on Refusal Appeal kind category: Appeal against decision to decline refusal Request date: 20180514 Decision date: 20190627 Appeal identifier: 2018101002079 |
|
| J121 | Written withdrawal of request for trial | ||
| PC1202 | Submission of document of withdrawal before decision of registration |
Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment) Patent event code: PC12021R01D Patent event date: 20190724 |
|
| PJ1201 | Withdrawal of trial |
Patent event code: PJ12011R01D Patent event date: 20190724 Comment text: Written Withdrawal of Request for Trial Appeal identifier: 2018101002079 Request date: 20180514 Appeal kind category: Appeal against decision to decline refusal Decision date: 20190627 |
|
| WITB | Written withdrawal of application |